Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder
CADTH
Record ID 32015000165
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir (SOF) be listed for the treatment of chronic hepatitis C (CHC) virus infection in adult patients with compensated liver disease, including cirrhosis, if criteria and conditions are met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0354_Abilify-MDD_Oct-24_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antidepressive Agents
- Depressive Disorder, Major
- Quinolones
- Piperazines
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.